Cerevel Therapeutics Holdings, Inc. (CERE)
NASDAQ (CM) NASDAQ (CM) Primary 
CEREVEL SHAREHOLDER ALERT: Cerevel Investors are Encouraged to Contact BFA Law About Ongoing Investigation into Whether the $45 Merger Offer is Too Low
NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
ACQUISITION NOTICE: Cerevel's (CERE) $45 Merger Offer is Being Investigated by BFA Law for Being Too Low, Shareholders are Encouraged Contact the Firm
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Cerevel Therapeutics: Time For A Risk Arbitrage Play?
Cerevel Therapeutics agreed to be acquired by AbbVie on 12/06/23 for $45/s or ~$8.7B. CERE stock closed on Friday, May 31st at $40.74/s. This presents investors with a potential arbitrage play of over 10% on a deal that should close within the next 3–6 months. There are significant risks to consider before making this type of investment.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
INVESTIGATION NOTICE (CERE): The $45 Per Cerevel Share Merger Offer Is Being Investigated by BFA Law for Being Too Low - Contact Firm for Information
NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
CEREVEL REMINDER: Cerevel (CERE) Shareholders are Encouraged to Inquire About BFA Law's Investigation into the $45 Merger Offer Being Too Low
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
CERE SHAREHOLDERS: Cerevel Shareholders are Encouraged to Inquire About BFA Law's Investigation into the $45 Merger Offer Being Too Low
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
Amalgamated Bank Has $425,000 Stock Holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)
Amalgamated Bank raised its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 8.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,027 shares of the biotechnology company’s stock after acquiring an additional 809 shares during the period. Amalgamated Bank’s holdings in Cerevel Therapeutics were worth $425,000 as of its most recent SEC filing. A number of other hedge funds also recently modified their holdings of the company. Graham Capital Management L.P. raised its stake in shares of Cerevel Therapeutics by 304.6% in the third quarter. Graham Capital Management L.P. now owns 41,850 shares of the biotechnology company’s stock valued at $914,000 after purchasing an additional 31,506 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Cerevel Therapeutics in the 3rd quarter valued at $1,092,000. Calamos Advisors LLC bought a new position in shares of Cerevel Therapeutics during the 4th quarter worth about $12,945,000. Charles Schwab Investment Management Inc. boosted its position in shares of Cerevel Therapeutics by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 517,244 shares of the biotechnology company’s stock valued at $11,291,000 after acquiring an additional 15,261 shares in the last quarter. Finally, Citigroup Inc. increased its stake in Cerevel Therapeutics by 22.7% in the third quarter. Citigroup Inc. now owns 83,786 shares of the biotechnology company’s stock valued at $1,829,000 after acquiring an additional 15,507 shares during the period. Institutional investors own 87.73% of the company’s stock. Insider Buying and Selling at Cerevel Therapeutics In other news, Director N Anthony Coles sold 50,000 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $41.01, for a total transaction of $2,050,500.00. Following the sale, the director now owns 15,638 shares in the company, valued at $641,314.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 150,000 shares of company stock worth $6,213,500. 5.10% of the stock is currently owned by insiders. Cerevel Therapeutics Price Performance Shares of CERE opened at $42.10 on Monday. Cerevel Therapeutics Holdings, Inc. has a one year low of $19.59 and a one year high of $43.59. The business’s 50 day simple moving average is $42.20 and its 200-day simple moving average is $39.21. The company has a debt-to-equity ratio of 0.60, a current ratio of 10.22 and a quick ratio of 10.22. Analyst Upgrades and Downgrades Separately, Mizuho lifted their price objective on Cerevel Therapeutics from $25.00 to $45.00 and gave the company a “neutral” rating in a report on Friday, February 16th. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Cerevel Therapeutics has an average rating of “Hold” and a consensus price target of $42.67. Get Our Latest Report on CERE Cerevel Therapeutics Company Profile (Free Report) Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.
